KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Common Equity for 16 consecutive years, with $789.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 1076.33% year-over-year to $789.2 million, compared with a TTM value of $789.2 million through Dec 2025, up 1076.33%, and an annual FY2025 reading of $789.2 million, up 1076.33% over the prior year.
  • Common Equity was $789.2 million for Q4 2025 at Alnylam Pharmaceuticals, up from $250.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $926.2 million in Q1 2021 and bottomed at -$408.1 million in Q2 2023.
  • Average Common Equity over 5 years is $181.8 million, with a median of $67.1 million recorded in 2024.
  • The sharpest move saw Common Equity plummeted 331.84% in 2023, then soared 8270.56% in 2025.
  • Year by year, Common Equity stood at $588.2 million in 2021, then tumbled by 126.9% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then skyrocketed by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025.
  • Business Quant data shows Common Equity for ALNY at $789.2 million in Q4 2025, $250.6 million in Q2 2025, and $115.4 million in Q1 2025.